Petrelintide is one of the most closely watched drugs currently moving through late-stage obesity trials, having just advanced into a large Phase 3 program. This guide covers what the compound actually is, how it's thought to work, and what has and hasn't been established about it so far.
What It Is
Petrelintide is a synthetic amylin analog developed by Zealand Pharma and now co-developed with Roche under a licensing agreement the two companies signed in 2025. It's designed as a long-acting compound given by once-weekly subcutaneous injection, for chronic weight management in people with overweight or obesity.
How Amylin Analogs Work
Amylin is a hormone released by the pancreas alongside insulin. Drugs that activate amylin receptors are thought to promote satiety and help restore sensitivity to leptin, a separate appetite-related hormone. That mechanism is distinct from GLP-1 receptor agonists such as semaglutide and tirzepatide, which act on a different hormonal pathway involved in blood sugar regulation and appetite. Amylin analogs are being developed both as standalone therapies and in combination with GLP-1 drugs, on the theory that targeting both pathways together could produce a stronger or more sustained effect than either alone; Novo Nordisk's CagriSema, which pairs the amylin analog cagrilintide with semaglutide, is one example of that combination approach already in late-stage testing.
What the Research Shows
Unlike many of the research-chemical peptides covered elsewhere on this site, petrelintide's evidence base is built on actual human clinical trials rather than animal or in vitro studies alone. Zealand Pharma has reported Phase 2 results describing "double-digit weight loss with a tolerability profile largely comparable to placebo," though the company has not published the full detailed dataset in a peer-reviewed journal as of this writing. That Phase 2 signal is what supported the decision to move into Phase 3.
The Phase 3 program, called ZUPREME, launched in September 2026 and consists of three trials enrolling a combined total of roughly 7,000 participants: one in people with overweight or obesity and related health conditions, one specifically in people with type 2 diabetes, and one in people with established cardiovascular disease that can run for up to three years. Those trials are designed to confirm whether the Phase 2 weight-loss and safety signals hold up across larger, more diverse, and higher-risk populations, including groups not well represented in the earlier testing.
Regulatory Status
Petrelintide is not approved by the FDA or any other regulatory body. It is strictly an investigational compound available only to people enrolled in its clinical trials; it is not available for prescription, and it should not be confused with FDA-approved amylin-pathway drugs like pramlintide, which is approved for diabetes but works differently and has a much longer track record.
Timeline and What to Watch
Based on the trial designs the companies have disclosed, the earlier two ZUPREME trials include maintenance phases running through week 64, and the cardiovascular trial is structured to run considerably longer. That means mature Phase 3 data, and any potential regulatory submission, remain years away even if the trials go well.
The Bottom Line
Petrelintide represents a genuinely different mechanism from the GLP-1 drugs that currently dominate the obesity treatment landscape, and it has real human trial data behind it rather than only preclinical research. But it remains unapproved and unproven at the scale now being tested, and anyone interested in amylin-pathway treatment options today should ask their doctor about what is currently FDA-approved rather than an investigational compound still years from potential approval.